AAV2-hAQP1基因治疗2-3级放射性晚期口干症的1期剂量递增研究
这项开放标签、多中心、剂量递增的1期研究纳入24例头颈部放疗后≥5年(HPV阳性≥2年)出现2-3级晚期口干症的患者,经Stensen导管向腮腺递送AAV2-hAQP1。未报告治疗相关严重不良事件或剂量限制性毒性,所有患者完成研究;第30天起全部患者报告结局显著改善并维持至12个月,双侧腺体治疗组改善更明显。
要点
- AAV2-hAQP1经腮腺导管递送安全耐受,无治疗相关严重不良事件或剂量限制性毒性。
- 第30天起所有患者报告结局显著改善,并维持至12个月,双侧治疗组改善更明显。
- 12个月时XQ总分平均较基线变化-39.5%,24例中16例(67%)XQ总分改善≥8分。
核心结论
- AAV2-hAQP1在所有剂量下安全且耐受良好,并带来口干症状和UWSFR的 meaningful 改善。
研究设计与样本
- 开放标签、多中心、剂量递增1期研究,纳入24例头颈部放疗后2-3级晚期口干症患者。
- 12例接受单侧腮腺注射,12例接受双侧腮腺注射,随访12个月。
主要发现
- 未报告治疗相关严重不良事件或剂量限制性毒性,所有参与者完成研究。
- 汇总所有队列数据,第30天全部患者报告结局出现统计学显著改善,并维持至第12个月。
- 第12个月XQ总分和MDASI-HN口干问题的平均较基线变化分别为-39.5%和-42.2%,GRCQ症状变化评分平均为3.8。
- 24例中16例(67%)XQ总分改善≥8分,19例(79%)基于GRCQ报告口干症状重要改善。
- 第12个月UWSFR平均较基线变化为112.5%。
临床怎么用
- 对于头颈部放疗后≥5年(HPV阳性≥2年)的2-3级晚期口干症患者,AAV2-hAQP1经腮腺导管递送可能改善症状和唾液流率。
- 双侧腮腺治疗组患者报告结局改善更明显,提示双侧给药可能更优。
局限性
- 本研究为开放标签、单臂设计,样本量24例,缺乏对照,结论需进一步随机对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Grade 2 and 3 late xerostomia is a chronic, debilitating complication of radiation therapy for head and neck cancers. We assessed the safety and efficacy of AAV2-hAQP1 gene therapy as a treatment for this condition. METHODS AND MATERIALS: Twenty-four participants who reported grade 2 and 3 late xerostomia at screening, ≥5 years after completing their final radiation therapy treatment (≥2 years if human papillomavirus-positive), were enrolled in this open-label, multicenter, dose-escalation study. AAV2-hAQP1 was delivered to the parotid gland(s) via cannulation of Stensen's duct. Twelve participants received AAV2-hAQP1 in 1 gland and 12 in both glands. Participants were followed for 12 months. Safety parameters included adverse events, physical examinations, laboratory tests, and electrocardiograms. Efficacy assessments included the Xerostomia-specific Questionnaire (XQ), MD Anderson Symptom Inventory-Head and Neck Module (MDASI-HN), Global Rate of Change Questionnaire (GRCQ), and measurement of unstimulated whole saliva flow rates (UWSFR). RESULTS: No treatment-related serious adverse events or dose-limiting toxicities were reported, and all participants completed the study. When the data from all cohorts were pooled, statistically significant improvements were seen on all patient-reported outcomes by day 30. These were maintained through month 12 with greater improvement in the bilateral cohort. At month 12, the mean percent change from baseline (%CFB) was -39.5% and -42.2% for the XQ Total Score and the MD Anderson Symptom Inventory-Head and Neck Module dry mouth question, respectively, and the mean GRCQ-Symptom Change Score was 3.8. Overall, 16 of 24 (67%) participants reported an improvement of ≥8 points in XQ Total Score, and 19 of 24 (79%) participants reported important improvements in xerostomia symptoms based on the GRCQ. The mean %CFB in UWSFR at month 12 was 112.5%. CONCLUSIONS: Treatment with AAV2-hAQP1 was safe and well-tolerated at all doses and resulted in meaningful improvements in xerostomia symptoms and UWSFR.
引用
- Brennan MT, Passineau MJ, Saunders D, et al. Results of a Phase 1 Open-Label, Dose-Escalation Study of Gene Therapy With AAV2-hAQP1 for Grade 2 and 3 Radiation-Induced Late Xerostomia and Parotid Gland Hypofunction. Int J Radiat Oncol Biol Phys. 2026. PMID: 42216935. doi:10.1016/j.ijrobp.2026.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。